Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2017.0100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Authors' Reply: Chronic Lesions in Scleroderma Renal Crisis: A Protective Clue?
J Am Soc Nephrol
September 2025
AP-HP, Nephrology Department, European Georges Pompidou Hospital, Paris, France.
The Safety Profile of Belzutifan in Renal Tumors: Real-World Data from a Tertiary Academic Center.
Oncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFIs Preoperative Anticoagulation in Nephrectomy with Caval Thrombectomy Necessary? A Multicenter Retrospective Cohort Study.
Eur Urol Open Sci
October 2025
Department of Urology, CHU Rennes, Rennes, France.
Background And Objective: Surgery of renal cell cancer (RCC) with a caval thrombus (CT) is associated with significant morbidity, particularly regarding thromboembolic complications. There are no data or recommendations regarding the potential benefit of preoperative anticoagulants. We aimed to assess the usefulness of preoperative anticoagulation regarding surgical outcomes and thromboembolic events in patients undergoing nephrectomy with inferior vena cava thrombectomy.
View Article and Find Full Text PDFIncidentally detected renal leiomyosarcoma with inferior vena cava tumor thrombus: a case report with review of the literature.
Front Surg
August 2025
Urology Department, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Kidney cancer is the 14th most common cancer worldwide. On the basis of the histological characteristics of kidney cancers, most kidney cancers are renal cell carcinomas. Renal leiomyosarcoma (LMS) is extremely rare and malignant and accounts for less than 1% of all kidney cancer cases.
View Article and Find Full Text PDFExperience With the Lattice Technique of Palliative Radiotherapy for Treating Voluminous Metastases of Renal Cancer in the Radiotherapy Department of Solca Quito, Ecuador: A Case Report.
Cureus
August 2025
College of Health Sciences, Universidad San Francisco de Quito, Quito, ECU.
Lattice radiotherapy (LRT) is a type of spatially fractionated radiation therapy (SFRT) that enables the delivery of ablative doses to specific internal regions of large tumoral lesions, while surrounding tissues and nearby critical structures receive significantly lower exposure. This technique relies on a spatial distribution strategy that allows dose levels of radiation to be applied within the tumor in a single session or, alternatively, over the course of five sessions. Over time, LRT has gained attention as a promising method for managing large tumors, especially in cases where conventional treatments may pose higher risks or be less effective, offering the benefit of reduced side effects.
View Article and Find Full Text PDF